PROBLEMS OF DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Highlights

In the modern literature, the algorithms for managing patients with CKD and ACS are not fully covered. However, approximately one in three ACS patients has CKD. To date, the frequency of using radial arterial access and intravascular imaging in patients with ACS and CKD in clinical practice is increasing, which significantly improves outcomes. However, many topics related to these issues remain poorly understood, so it is necessary to conduct specialized studies among all stages of CKD, taking into account eGFR, and the severity of albuminuria.

Abstract

The number of patients suffering from chronic kidney disease (CKD) is growing progressively, in half of the cases they die from cardiovascular diseases (CVD) before they reach the terminal stage of renal failure. Patients with CKD belong to a special group of the population when considering ACS therapy. CKD complicates diagnosis, risk stratification, pharmacological therapy, invasive treatment, and ACS outcomes. The purpose of the review is to analyze the domestic and foreign literature on the management of ACS in patients with CKD, as well as to offer practical recommendations for practitioners and identify current knowledge gaps that require further research. ACS makes a significant contribution to the morbidity and mortality of patients with CKD, which makes it extremely relevant to study the features of ACS management in this group of patients. It is not uncommon for patients and clinicians to reject scientifically based diagnostic and therapeutic methods due to concerns about worsening renal failure. Although overcoming this phenomenon partly depends on following the recommendations, a complete solution to the problem will equally depend on a proper assessment of the risks, pharmacological and invasive factors characteristic of patients with CKD. To date, the frequency of using radial arterial access and intravascular imaging in patients with ACS and CKD in clinical practice is increasing, which significantly improves outcomes. Nevertheless, a large number of knowledge gaps remain, so it is necessary to conduct specialized studies among all stages of CKD, not only taking into account eGFR, but also the severity of albuminuria. It is important to note that this will require better representation of CKD patients in randomized trials.

1. Barbarash O.L., Kashtalap V.V. Non-ST segment elevation myocardial infarction: results of 2021−2022. Fundamental and Clinical Medicine. 2023;8(1):132-142. doi:10.23946/2500-0764-2023-8-1-132-142 (In Russian)

2. Alidzhanova K.G., Rzhevskaya O.N., Sagirov M.A., Gazaryan G.A. Prognostic importance of chronic kidney disease in patients with acute coronary syndrome. Russian Sklifosovsky Journal.Emergency Medical Care. 2017;6(2):132-139. doi: 10.23934/2223-9022-2017-6-2132-139(In Russian)

3. Evseeva MV, Karetnikova VN, Barbarash OL. Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus. Therapeutic Archive. 2015;87(1):105 108. doi:10.17116/terarkh2015871105-108. (In Russian)

4. Karetnikova V. N., Kalaeva V. V., Evseeva M. V., Osokina A.V., Kashtalap V.V., Gruzdeva O.V., Shafranskaia K.S., Zykov M.V., Barbarash O.L.The role of chronic kidney disease in assessing the risk of an unfavorable course of the hospital period of myocardial infarction with ST segment elevation. Therapeutic Archive. 2016;88(6):26-32. doi:10.17116/terarkh201688626-32(In Russian)

5. Bagai A., Lu D., Lucas J., Goyal A., Herzog C.A., Wang T.Y., Goodman S.G., Roe M.T.Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry. J Am Heart Assoc. 2018;7(24):e010394. doi: 10.1161/JAHA.118.010394.

6. Rzhevskaya O.N., Moiseyeva A.Y., Esaulenko A.N., Pinchuk A.V., Alidzhanova Kh.G. Chronic Kidney Disease and Myocardial Infarction. Russian Sklifosovsky Journal "Emergency Medical Care". 2022;11(1):104-118. doi: 10.23934/2223-9022-2022-11-1-104-118 (In Russian)

7. Khalikov A.A., Kuznetsov K.O., Iskuzhina L.R., Khalikova L.V. Forensic aspects of sudden autopsy-negative cardiac death. Forensic Medical Expertise. 2021;64(3):59 63 doi:10.17116/sudmed20216403159 (In Russian)

8. Kühn A., van der Giet M., Kuhlmann M.K., Martus P., Mielke N., Ebert N., Schaeffner E.S. Kidney Function as Risk Factor and Predictor of Cardiovascular Outcomes and Mortality Among Older Adults. Am J Kidney Dis. 2021;77(3):386-396. doi: 10.1053/j.ajkd.2020.09.015.

9. Gulati M., Levy P.D., Mukherjee D., Amsterdam E., Bhatt D.L., Birtcher K.K., Blankstein R., Boyd J., Bullock-Palmer R.P., Conejo T., Diercks D.B., Gentile F., Greenwood J.P., Hess E.P., Hollenberg S.M., Jaber W.A., Jneid H., Joglar J.A., Morrow D.A., O'Connor R.E., Ross M.A., Shaw L.J. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):368-454. doi: 10.1161/CIR.0000000000001029.

10. Milovanova L.Yu., Beketov V.D., Milovanova S.Yu., Taranova M.V., Filippova A.A., Pasechnik A.I. Biomarkers ofheart and vascular lesions in the framework of mineral and bone disorders in chronic kidney disease, correction possibilities. Klinicheskaya meditsina. 2021;99(4):245-258. doi: 10.30629/0023-2149-2021-99-4-245-258 (In Russian)

11. Banerjee D., Perrett C., Banerjee A. Troponins, Acute Coronary Syndrome and Renal Disease: From Acute Kidney Injury Through End-stage Kidney Disease. Eur Cardiol. 2019;14(3):187-190. doi: 10.15420/ecr.2019.28.2

12. Chaulin AM, Karslyan LS, Duplyakov DV. Non-Coronarogenic Causes of Increased Cardiac Troponins in Clinical Practice. Journal of Clinical Practice. 2019;10(4):81-93. doi: 10.17816/ clinpract16309(In Russian)

13. Braghieri L., Badwan O.Z., Skoza W., Fares M., Menon V. Evaluating troponin elevation in patients with chronic kidney disease and suspected acute coronary syndrome. Cleve Clin J Med. 2023;90(8):483-489. doi: 10.3949/ccjm.90a.23012.

14. Vorobyev E.A., Galkina O.V., Zubina I.M., Bogdanova E.O., Levy`kina E.N., Kucher A.G. Аpplication of myocardial damage and heart failure biomarkers in preventive and early diagnosis of aki in acute coronary syndrome. Nephrology (Saint-Petersburg). 2020;24(6):28-39. doi:10.36485/1561-6274-2020-24-6-28-39 (In Russian)

15. Turakhia M.P., Blankestijn P.J., Carrero J., Clase C.M., Deo R., Herzog Ch.A., Kasner S.E., Passman R.S., Pecoits-Filho R., Reinecke H., Shrof G.R., Zareba W., Cheung M., Wheeler D.C., Wanner Ch., Winkelmayer W.C. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (kdigo) controversies conference. Nephrology (Saint-Petersburg). 2019;23(2):18-40. doi: 10.24884/1561-6274-2019-23-2-18-40 (In Russian)

16. Alvin M.D., Jaffe A.S., Ziegelstein R.C., Trost J.C. Eliminating Creatine Kinase-Myocardial Band Testing in Suspected Acute Coronary Syndrome: A Value-Based Quality Improvement. JAMA Intern Med. 2017;177(10):1508-1512. doi: 10.1001/jamainternmed.2017.3597.

17. Korzukhin A.Yu., Yuldoshev J.R., Troshina A.A., Khuramshina L.R., Guzarik V.N., Dyrnaeva A.D., Safin L.F., Nurislamov A.F., Enikeev I.M., Shaizhanova A.A., Natalenko A.A., Nodirov M.N. Type 2 myocardial infarction: diagnostic and therapeutic difficulties in modern cardiology. Complex Issues of Cardiovascular Diseases. 2023;12(3):84-97. doi:10.17802/2306-1278-2023-12-3-84-97 (In Russian)

18. Laureano-Phillips J., Robinson R.D., Aryal S., Blair S., Wilson D., Boyd K., Schrader C.D., Zenarosa N.R., Wang H. HEART Score Risk Stratification of Low-Risk Chest Pain Patients in the Emergency Department: A Systematic Review and Meta-Analysis. Ann Emerg Med. 2019;74(2):187-203. doi: 10.1016/j.annemergmed.2018.12.010.

19. Shafi S., Saleem M., Anjum R., Abdullah W., Shafi T. ECG Abnormalities In Patients With Chronic Kidney Disease. J Ayub Med Coll Abbottabad. 2017;29(1):61-64.

20. Hira R.S. Care of Patients With Chronic Kidney Disease Presenting With Acute Coronary Syndrome: Improved, But Not Good Enough. J Am Heart Assoc. 2018;7(24):e011254. doi: 10.1161/JAHA.118.011254.

21. Kim Y.H., Her A.Y., Jeong M.H., Kim B.K., Hong S.J., Lee S.J., Ahn C.M., Kim J.S., Ko Y.G., Choi D., Hong M.K., Jang Y. Two-year outcomes between ST-elevation and non-ST-elevation myocardial infarction in patients with chronic kidney disease undergoing newer-generation drug-eluting stent implantation. Catheter Cardiovasc Interv. 2022;99(4):1022-1037. doi: 10.1002/ccd.30049.

22. Nakano M., Ogata N. Is "Renalism" No Longer an Obstacle to Angiography and Intervention in Patients With Chronic Kidney Disease? Circ J. 2022;86(5):797-798. doi: 10.1253/circj.CJ-22-0141.

23. Bansal N., Zelnick L.R., Scherzer R., Estrella M., Shlipak M.G. Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease. Circ Heart Fail. 2024;17(5):e011173. doi: 10.1161/CIRCHEARTFAILURE.123.011173.

24. Weisbord S.D., Palevsky P.M., Kaufman J.S., Wu H., Androsenko M., Ferguson R.E., Parikh C.R., Bhatt D.L., Gallagher M.; PRESERVE Trial Investigators. Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography. J Am Coll Cardiol. 2020;75(11):1311-1320. doi: 10.1016/j.jacc.2020.01.023

25. Wilson T.A., Hazlewood G.S., Sajobi T.T., Wilton S.B., Pearson W.E., Connolly C., Javaheri P.A., Finlay J.L., Levin A., Graham M.M., Tonelli M., James M.T. Preferences of patients with chronic kidney disease for invasive versus conservative treatment of acute coronary syndrome: a discrete choice experiment. J Am Heart Assoc. 2023;12(6):e028492. doi:10.1161/JAHA.122.028492

26. Washam J.B., Herzog C.A., Beitelshees A.L., Cohen M.G., Henry T.D., Kapur N.K., Mega J.L., Menon V., Page R.L. 2nd, Newby L.K.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131(12):1123–1149. doi: 10.1161/CIR.0000000000000183

27. Urban P., Mehran R., Colleran R., Angiolillo D.J., Byrne R.A., Capodanno D., Cuisset T., Cutlip D., Eerdmans P., et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–261. doi: 10.1161/CIRCULATIONAHA.119.040167.

28. Stefanini G.G., Briguori C., Cao D., Baber U., Sartori S., Zhang Z., et al. Ticagrelor monotherapy in patients with chronic kid- ney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021;42(45):4683–4693. doi: 10.1093/eurheartj/ehab533

29. Kokozheva M.A., Mardanov B.U., Mamedov M.N. Acute coronary syndrome in diabetes mellitus: features of pathogenesis, course and therapy. Russian Journal of Preventive Medicine. 2021;24(2):89‑96. doi: 10.17116/profmed20212402189(In Russian)

30. Gao C., Tomaniak M., Takahashi K., Kawashima H., Wang R., Hara H., Ono M., Montalescot G., Garg S., Haude M., Slagboom T., Vranckx P., Valgimigli M., Windecker S., van Geuns R.J., Hamm C., Steg P.G., Onuma Y., Angiolillo D.J., Serruys P.W. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol. 2020;19(1):179. doi: 10.1186/s12933-020-01153-x

31. Guskova E.V., Panchenko E.P., Komarov A.L., Dobrovolsky A.B., Samko A.N. Residual platelet reactivity to ADP and the risk of bleeding in stable chd patients receiving double antiplatelet therapy for elective percutaneous coronary intervention. Russian Journal of Cardiology. 2015;(3):35-42. doi:10.15829/1560-4071-2015-3-35-42 (In Russian)

32. Guo Y., Zhang Y., Zhao J., Wu L., Yu Z., He D., Huang H., Luo X. Impact of Diabetes on Platelet Function in Acute Ischemic Stroke Patients Taking Dual Antiplatelet Therapy. Front Neurol. 2021;12:712024. doi: 10.3389/fneur.2021.712024.

33. Berger M., Dressel A., Kleber M.E., März W., Hellstern P., Marx N., Schütt K. Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study. J Clin Med. 2023;12(5):1913. doi: 10.3390/jcm12051913.

34. Shoji S., Sawano M., Sandhu A.T., Heidenreich P.A., Shiraishi Y., Ikemura N., Ueno K., Suzuki M., Numasawa Y., Fukuda K., Kohsaka S. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA Netw Open. 2020;3(4):e202004. doi: 10.1001/jamanetworkopen.2020.2004.

35. Mullen L., Meah M.N., Elamin A., Aggarwal S., Shahzad A., Shaw M., Hasara J., Rashid M., Fisher M., Ali T., Patel B., Ding W.Y., Grainger R., Heseltine T., Kirmani B.H., Obeidat M., Kasolo Y., Thatchil J., Khand A. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. J Am Heart Assoc. 2021;10(8):e019467. doi: 10.1161/JAHA.120.019467.

36. Rymer J.A., Kaltenbach L.A., Doll J.A., Messenger J.C., Peterson E.D., Wang T.Y. Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease. J Am Heart Assoc. 2019;8(10): e012236. doi: 10.1161/JAHA.119.012236

37. Crea F. Challenges of antithrombotic treatment in high-risk populations and a fond farewell to CKMB. Eur Heart J. 2021;42(23):2221-2224. doi: 10.1093/eurheartj/ehab345

38. Mavrakanas T.A., Chatzizisis Y.S., Gariani K., Kereiakes D.J., Gargiulo G., Helft G., Gilard M., Feres F., Costa R.A., Morice M.C., Georges J.L., Valgimigli M., Bhatt D.L., Mauri L., Charytan D.M. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol. 2019;14(6):810–22. doi: 10.2215/CJN.12901018

39. Ying S, Li X. Renal insufficiency and outcomes in patients with acute coronary syndrome. Int J Cardiol. 2021;327:36. doi: 10.1016/j.ijcard.2020.11.054.

40. Rosenthal N., Xiao Z., Kartashov A., Levorsen A., Shah B.R. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome. Am J Cardiovasc Drugs. 2021;21(1):93-101. doi: 10.1007/s40256-020-00419-9.

41. Pinto C.A., Chua G.N., Bridges J.F.P., Brookes E., Hyacinthe J., Tervonen T. Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment. Patient. 2022;15(2):255-266. doi: 10.1007/s40271-021-00548-6.

42. Weerasaksanti A., Siwamogsatham S., Kunlamas Y., Bunditanukul K. Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome. BMC Cardiovasc Disord. 2023;23(1):243. doi: 10.1186/s12872-023-03278-9.

43. Amsterdam E.A., Wenger N.K., Brindis R.G., Casey D.E. Jr., Ganiats T.G., Holmes D.R. Jr., Jaffe A.S., Jneid H., Kelly R.F., Kontos M.C., Levine G.N., Liebson P.R., Mukherjee D., Peterson E.D., Sabatine M.S., Smalling R.W., Zieman S.J. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. Circulation. 2014;130(25):344–426. doi: 10.1161/CIR.0000000000000134.

44. Shaikh S.A., Regal R.E. Dosing of enoxaparin in renal impairment. P T. 2017;42(4):245–249.

45. Melloni C., Peterson E.D., Chen A.Y., Szczech L.A., Newby L.K., Harrington R.A., Gibler W.B., Ohman E.M., Spinler S.A., Roe M.T., Alexander K.P.Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008;51(10):991–996. doi: 10.1016/j.jacc.2007.11.045.

46. Natanzon S.S., Matetzky S., Beigel R., Iakobishvili Z., Goldenberg I., Shechter M.; Acute Coronary Syndrome Israel Survey (ACSIS) investigators.Statin therapy among chronic kidney disease patients presenting with acute coronary syndrome. Atherosclerosis. 2019;286:14–19. doi: 10.1016/j.atherosclerosis.2019.05.002

47. Shimada T., Osakada K., Okabe K., Shima Y., Eguchi H., Habara S., Tada T., Taguchi Y., Ikuta A., Takamatsu M., Murai R., Miura K., Ohya M., Amano H., Kubo S., Tanaka H., Maruo T., Fuku Y., Katoh H., Goto T., Kadota K. Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction. Heart Vessels. 2021;36(3):297-307. doi: 10.1007/s00380-020-01696-9.

48. Kang M.H., Kim W., Kim J.S., Jeong K.H., Jeong M.H., Hwang J.Y., Hur S.H., Hwang H.S. Hydrophilic Versus Lipophilic Statin Treatments in Patients With Renal Impairment After Acute Myocardial Infarction. J Am Heart Assoc. 2022;11(11):e024649. doi: 10.1161/JAHA.121.024649.

49. Morita T., Morimoto S., Nakano C., Kubo R., Okuno Y., Seo M., Someya K., Nakahigashi M., Ueda H., Toyoda N., Kusabe M., Jo F., Takahashi N., Iwasaka T., Shiojima I. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014;53(4):307–314. doi: 10.2169/internalmedicine.53.0649

50. Igweonu-Nwakile E.O., Ali S., Paul S., Yakkali S., Teresa Selvin S., Thomas S., Bikeyeva V., Abdullah A., Radivojevic A., Abu Jad A.A., Ravanavena A., Ravindra C., Balani P. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus. 2022;14(9):e29140. doi: 10.7759/cureus.29140.

51. Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M.,et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):18–114. doi: 10.1161/CIR.0000000000001038

52. Sinitsin V.E., Filatova D.A., Mershina E.A. Contrast-induced acute renal injury: the modern state of issue. Medical Visualization. 2022;26(1):27-39. doi:10.24835/10.24835/1607-0763-1088. (In Russian)

53. Mehran R., Owen R., Chiarito M., Baber U., Sartori S., Cao D., Nicolas J., Pivato C.A., Nardin M., Krishnan P., Kini A., Sharma S., Pocock S., Dangas G. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021;398(10315):1974–83. Doi: 10.1016/S0140-6736(21)02326-6

54. Landi A., Chiarito M., Branca M., Frigoli E., Gagnor A., Calabrò P., Briguori C., Andò G., Repetto A., Limbruno U., Sganzerla P., Lupi A., Cortese B., Ausiello A., Ierna S., Esposito G., Ferrante G., Santarelli A., Sardella G., Varbella F., Heg D., Mehran R., Valgimigli M.Validation of a contemporary acute kidney injury risk score in patients with acute coronary syndrome. JACC Cardiovasc Interv. 2023;16(15):1873–1886. doi: 10.1016/j.jcin.2023.06.015

55. Giacoppo D., Gargiulo G., Buccheri S., Aruta P., Byrne R.A., Cassese S., Dangas G., Kastrati A., Mehran R., Tamburino C., Capodanno D. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28 240 patients. Circulation: Cardiovascular Interventions. 2017;10(5):e004383. doi: 10.1161/CIRCINTERVENTIONS.116.004383

56. Qian G., Fu Z., Guo J., Cao F., Chen Y. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv. 2016;9(1):89–96. doi: 10.1016/j.jcin.2015.09.026

57. Brar S.S., Aharonian V., Mansukhani P., Moore N., Shen A.Y., Jorgensen M., Dua A., Short L., Kane K. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814–1823. doi: 10.1016/S0140-6736(14)60689-9.

58. Yan Y., Ye M., Dong X., Chen Q., Hong H., Chen L., Luo Y. Prevention of contrast-induced nephropathy by inferior vena cava ultrasonography-guided hydration in chronic heart failure patients. Cardiology. 2021;146(2):187–194. doi: 10.1159/000512434.

59. Fayed A., Hammad A.A., Abdulazim D.O., Hammad H., Amin M., Elhadidy S., Salem M.M., ElAzim I.M.A., Zsom L., Csongradi E., Soliman K.M., Sharaf ElDin U.A. Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study. Ren Fail. 2023;45(1):2194434. doi: 10.1080/0886022X.2023.2194434

60. Maioli M., Toso A., Leoncini M., Musilli N., Grippo G., Ronco C., McCullough P.A., Bellandi F. Bioimpedance-guided hydration for the prevention of contrast-induced kidney injury: the HYDRA study. J Am Coll Cardiol. 2018;71(25):2880–2889. doi: 10.1016/j.jacc.2018.04.022

61. Moroni F., Baldetti L., Kabali C., Briguori C., Maioli M., Toso A., Brilakis E.S., Gurm H.S., Bagur R., Azzalini L. Tailored versus standard hydration to prevent acute kidney injury after percutaneous coronary intervention: network meta-analysis. J Am Heart Assoc. 2021;10(13):e021342. doi: 10.1161/JAHA.121.021342

62. Lombardi M., Molisana M., Genovesi E., De Innocentiis C., Limbruno U., Misuraca L., Moretti L., Di Vito L., Renda G., Zimarino M., Di Nicola M., De Caterina R. Urine alkalinisation to prevent contrast-induced acute kidney injury: the prospective, randomised, controlled, open-label TEATE trial. EuroIntervention. 2022;18(7):562–573. doi: 10.4244/EIJ-D-22-00010.

63. Thiele H., Akin I., Sandri M., Fuernau G., de Waha S., Meyer-Saraei R.,et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419–32. doi: 10.1056/NEJMoa1710261.

64. Mariani J., Guedes C., Soares P., Zalc S., Campos C.M., Lopes A.C., Spadaro A.G., Perin M.A., Filho A.E., Takimura C.K., Ribeiro E., Kalil-Filho R., Edelman E.R., Serruys P.W., Lemos P.A. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial. JACC: Cardiovascular Interventions. 2014;7(11):1287–1293. doi: 10.1016/j.jcin.2014.05.024

65. Freitas R.A.P., Tanajura L.F., Mehran R., hamié D., Chaves A., Centemero M., Braga S., Costa R., Cao D., Sousa A., Feres F., Costa J.R. Jr. Ioxaglate versus iodixanol for the prevention of contrast-induced nephropathy: the IDPC trial. J Invasive Cardiol. 2023;35(6):281–290. doi: 10.25270/jic/21.00249.

66. Andò G., Cortese B., Russo F., Rothenbühler M., Frigoli E., Gargiulo G., et al. Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX. J Am Coll Cardiol. 2017;69(21):2592–2603. doi: 10.1016/j.jacc.2017.02.070

67. Zhang P., Li W.Y., Yang S.C., Fu N.K., Liu X.G., Zhang X., Cong H.L., Lin W.H., Tian F.S., Lu C.Z., Zhang J. Preventive effects of nicorandil against contrast-induced nephropathy in patients with moderate renal insufficiency undergoing percutaneous coronary intervention. Angiology. 2020;71(2):183–188. doi: 10.1177/0003319719841733

68. Bafna A.A., Shah H.C. Remote ischemic preconditioning for prevention of contrast-induced nephropathy - a randomized control trial. Indian Heart J. 2020;72(4):244–247. doi: 10.1016/j.ihj.2020.04.010.

69. Panagiotou A., Trendelenburg M., Heijnen I.A.F.M., Moser S., Bonati L.H., Breidthardt T., Fahrni G., Kaiser C., Jeger R., Osthoff M. A randomized trial of recombinant human C1-esterase-inhibitor in the prevention of contrast-induced kidney injury. JACC Cardiovasc Interv. 2020;13(7):833–842. doi: 10.1016/j.jcin.2019.11.021.

70. Beirne A.M., Mitchelmore O., Palma S., Andiapen M., Rathod K.S., Hammond V., Bellin A., Cooper J., Wright P., Antoniou S., Yaqoob M.M., Naci H., Mathur A., Ahluwalia A., Jones D.A. NITRATE-CIN study: protocol of a randomized (1:1) single-center, UK, double-blind placebo-controlled trial testing the effect of inorganic nitrate on contrast-induced nephropathy in patients undergoing coronary angiography for acute coronary syndromes. J Cardiovasc Pharmacol Ther. 2021;26(4):303–309. doi: 10.1177/1074248421000520.

71. Shrivastava A., Nath R.K., Mahapatra H.S., Pandit B.N., Raj A., Sharma A.K., Kumar T., Kuber D., Aggarwal P. Ultra-low contrast PCI vs conventional PCI in patients of ACS with increased risk of CI-AKI (CONSaVE-AKI). Indian Heart J. 2022;74(5):363–368. doi: 10.1016/j.ihj.2022.08.004.

72. Hutcheson J.D., Goettsch C. Cardiovascular calcification heterogeneity in chronic kidney disease. Circ Res. 2023;132(8):993–1012. doi: 10.1161/CIRCRESAHA.123.321760.

73. Tomey M.I., Sharma S.K. Interventional options for coronary artery calcification. Curr Cardiol Rep. 2016;18(2):12. doi: 10.1007/s11886-015-0691-8.

74. Hennessey B., Messenger J.C., Kirtane A.J., Parikh M., Danenberg H., De Vroey F., Curcio A., Eshuis P., Escaned J. Rationale and design of the dynamic coronary roadmap for contrast reduction (DCR4Contrast) in PCI randomized controlled trial. Am Heart J. 2023;263:151–158. doi: 10.1016/j.ahj.2023.04.004